Show simple item record

dc.contributor.authorHerrán Martínez, Enara
dc.contributor.authorRequejo Rodríguez, Catalina ORCID
dc.contributor.authorRuiz Ortega, José Ángel
dc.contributor.authorAristieta Arbelaiz, Asier
dc.contributor.authorIgartua Olaechea, Manuela ORCID
dc.contributor.authorBengoetxea Odriozola, Harkaitz
dc.contributor.authorUgedo Urruela, Luisa
dc.contributor.authorPedraz Muñoz, José Luis ORCID
dc.contributor.authorLafuente Sánchez, José Vicente ORCID
dc.contributor.authorHernández Martín, Rosa María ORCID
dc.date.accessioned2016-03-18T14:38:39Z
dc.date.available2016-03-18T14:38:39Z
dc.date.issued2014
dc.identifier.citationInternational Journal of Nanomedicine 9 : 2677-2687(2014)es
dc.identifier.issn1178-2013
dc.identifier.urihttp://hdl.handle.net/10810/17706
dc.description.abstractCurrent research efforts are focused on the application of growth factors, such as glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF), as neuroregenerative approaches that will prevent the neurodegenerative process in Parkinson's disease. Continuing a previous work published by our research group, and with the aim to overcome different limitations related to growth factor administration, VEGF and GDNF were encapsulated in poly(lactic-co-glycolic acid) nanospheres (NS). This strategy facilitates the combined administration of the VEGF and GDNF into the brain of 6-hydroxydopamine (6-OHDA) partially lesioned rats, resulting in a continuous and simultaneous drug release. The NS particle size was about 200 nm and the simultaneous addition of VEGF NS and GDNF NS resulted in significant protection of the PC-12 cell line against 6-OHDA in vitro. Once the poly(lactic-co-glycolic acid) NS were implanted into the striatum of 6-OHDA partially lesioned rats, the amphetamine rotation behavior test was carried out over 10 weeks, in order to check for in vivo efficacy. The results showed that VEGF NS and GDNF NS significantly decreased the number of amphetamine-induced rotations at the end of the study. In addition, tyrosine hydroxylase immunohistochemical analysis in the striatum and the external substantia nigra confirmed a significant enhancement of neurons in the VEGF NS and GDNF NS treatment group. The synergistic effect of VEGF NS and GDNF NS allows for a reduction of the dose by half, and may be a valuable neurogenerative/neuroreparative approach for treating Parkinson's disease.es
dc.description.sponsorshipThe "Ministerio de Ciencia e Innovacion" (SAF2010-20375), the University of the Basque Country (UPV/EHU) (UFI 11/32), the Basque Government (Saiotek SA-2010/00028), and FEDER funds partially supported this project. The authors are grateful for the cooperation of SGIker (UPV/EHU, MICINN, GV/EJ, ESF). E Herran appreciates the Basque Government fellowship subvention, and C Requejo and A Aristieta thank UPV/EHU for a fellowship subvention. We thank Dr A Krzyzanowska for the careful revision of the manuscript.es
dc.language.isoenges
dc.publisherDove Medical Presses
dc.relationinfo:eu-repo/grantAgreement/MICINN/SAF2010-20375
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectnanoparticleses
dc.subjectPLGAes
dc.subject6-OHDAes
dc.subjectneuroregenerationes
dc.subjectneurotrophic factorses
dc.subjecttyrosine hydroxylasees
dc.subjectdopaminergic-neuronses
dc.subjectneurodegenerative diseaseses
dc.subjectdelivery systemses
dc.subjectin-vitroes
dc.subjectcellses
dc.subjectneuroprotectiones
dc.subjectbraines
dc.subjectmicrosphereses
dc.subjectstriatumes
dc.titleIncreased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's diseasees
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holderThis work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.es
dc.relation.publisherversionhttps://www.dovepress.com/increased-antiparkinson-efficacy-of-the-combined-administration-of-veg-peer-reviewed-article-Ies
dc.identifier.doi10.2147/IJN.S61940
dc.departamentoesNeurocienciases_ES
dc.departamentoesFarmacia y ciencias de los alimentoses_ES
dc.departamentoesFarmacologíaes_ES
dc.departamentoeuNeurozientziakes_ES
dc.departamentoeuFarmazia eta elikagaien zientziakes_ES
dc.departamentoeuFarmakologiaes_ES
dc.subject.categoriaBIOENGINEERING
dc.subject.categoriaMATERIALS SCIENCE, BIOMATERIALS
dc.subject.categoriaDRUG DISCOVERY
dc.subject.categoriaCHEMISTRY, ORGANIC
dc.subject.categoriaBIOPHYSICS


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record